Despite its success in treating other cancers, immunotherapy for ovarian cancer only boasts a 6-15% success rate. The reasons behind this disparity are complex, but PhD student, Karla Robles, is determined to change this narrative. Making this research even more critical is the alarming fact that while Black women are less likely to develop ovarian
Dr. David Schlundt, a long-time professor of psychology at Vanderbilt University, has spent decades studying the intersection between health and behavior. His research career, which began in 1985, has taken him from eating disorder clinics to diabetes centers to community health initiatives, always with a focus on how our environment and behaviors shape our well-being.
Meharry-Vanderbilt-Tennessee State University Cancer Partnership (MVTCP): Vanderbilt Medical Cancer Research Experience (please see attached pdf) Only Vanderbilt medical students are eligible, but they can work with any MVTCP investigator. $3K to support research activities (including attendance at a scientific meeting) Short application required: https://redcap.link/MVTCP23-24
A new study authored by Vishal R. Patel, BS, Dr. Alex B. Haynes, MD, MPH (Dell Medical School, The University of Texas at Austin), Dr. Karen Winkfield, M.D., PhD (Meharry-Vanderbilt Alliance, Vanderbilt University Medical Center, Nashville, TN), Dr. Arjun Gupta, MD, Dr. Anne H. Blaes, MD, MS (Masonic Cancer Center, University of Minnesota, Minneapolis), Dr.
